Lifecore Biomedical
LFCR
82 hedge funds and large institutions have $85.6M invested in Lifecore Biomedical in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 28 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
17% more call options, than puts
Call options by funds: $124K | Put options by funds: $106K
2.73% less ownership
Funds ownership: 77.47% → 74.74% (-2.7%)
11% less funds holding
Funds holding: 92 → 82 (-10)
36% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 28
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
42% less capital invested
Capital invested by funds: $149M → $85.6M (-$63M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
+$5.77M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.65M |
| 3 |
WC
Wynnefield Capital
New York
|
+$2.57M |
| 4 |
Morgan Stanley
New York
|
+$1.28M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
-$5.03M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$3.91M |
| 3 |
PRCP
Pacific Ridge Capital Partners
Lake Oswego,
Oregon
|
-$2.7M |
| 4 |
ICM
ISZO Capital Management
New York
|
-$2.42M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.32M |
LFCR Hedge Fund Activity: Q1 2023 in Review
82 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2023, worth a combined $85.6M — down 42% from $149M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of LFCR and 18 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 26 added.
The largest buyer was Greenhaven Road Investment Management, opening a new position worth an estimated $5.77M. The largest seller was Punch & Associates Investment Management, exiting entirely with an estimated $5.03M sold.
- 82 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2023, down from 92 in Q4 2022.
- Funds reported $85.6M of Lifecore Biomedical stock for Q1 2023, down 42% quarter-over-quarter.
- 18 funds opened new Lifecore Biomedical positions in Q1 2023 and 28 closed out, a net change of -10 holders.
- The largest Lifecore Biomedical buyer in Q1 2023 was Greenhaven Road Investment Management, an estimated $5.77M added.
- The largest Lifecore Biomedical seller in Q1 2023 was Punch & Associates Investment Management, an estimated $5.03M sold.
Based on aggregated 13F filings for Q1 2023.